Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Ponesimod reduces annualized relapse rate, compared with teriflunomide

Key clinical point: Ponesimod reduces the number of confirmed MS relapses, compared with teriflunomide.

Major finding: Annualized relapse rate was 30.5% lower with ponesimod, compared with teriflunomide.

Study details: A randomized, double-blind, superiority study of 1,133 patients with relapsing-remitting MS.

Disclosures: Actelion Pharmaceuticals sponsored the study.